rs148789453
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000203.5(IDUA):c.713T>A(p.Leu238Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000561 in 1,604,640 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 34)
Exomes 𝑓: 0.0000041 ( 0 hom. )
Consequence
IDUA
NM_000203.5 missense
NM_000203.5 missense
Scores
9
8
2
Clinical Significance
Conservation
PhyloP100: 6.04
Genes affected
IDUA (HGNC:5391): (alpha-L-iduronidase) This gene encodes an enzyme that hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. This hydrolysis is required for the lysosomal degradation of these glycosaminoglycans. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I). [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.973
PP5
Variant 4-1001802-T-A is Pathogenic according to our data. Variant chr4-1001802-T-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 265418.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IDUA | NM_000203.5 | c.713T>A | p.Leu238Gln | missense_variant | 6/14 | ENST00000514224.2 | NP_000194.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IDUA | ENST00000514224.2 | c.713T>A | p.Leu238Gln | missense_variant | 6/14 | 2 | NM_000203.5 | ENSP00000425081 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152184Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
3
AN:
152184
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000218 AC: 5AN: 229094Hom.: 0 AF XY: 0.0000239 AC XY: 3AN XY: 125528
GnomAD3 exomes
AF:
AC:
5
AN:
229094
Hom.:
AF XY:
AC XY:
3
AN XY:
125528
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000413 AC: 6AN: 1452456Hom.: 0 Cov.: 34 AF XY: 0.00000554 AC XY: 4AN XY: 722324
GnomAD4 exome
AF:
AC:
6
AN:
1452456
Hom.:
Cov.:
34
AF XY:
AC XY:
4
AN XY:
722324
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152184Hom.: 0 Cov.: 34 AF XY: 0.0000269 AC XY: 2AN XY: 74340
GnomAD4 genome
AF:
AC:
3
AN:
152184
Hom.:
Cov.:
34
AF XY:
AC XY:
2
AN XY:
74340
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Mucopolysaccharidosis type 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | This sequence change replaces leucine, which is neutral and non-polar, with glutamine, which is neutral and polar, at codon 238 of the IDUA protein (p.Leu238Gln). This variant is present in population databases (rs148789453, gnomAD 0.008%). This missense change has been observed in individual(s) with mucopolysaccharidosis type I (PMID: 15300847, 24368159; Invitae). ClinVar contains an entry for this variant (Variation ID: 265418). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt IDUA protein function with a positive predictive value of 95%. This variant disrupts the p.Leu238 amino acid residue in IDUA. Other variant(s) that disrupt this residue have been observed in individuals with IDUA-related conditions (PMID: 21480867, 24368159), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 14, 2020 | The p.Leu238Gln variant in IDUA has been reported in at least 7 individuals with mucopolysaccharidosis (MPS), segregated with disease in 4 affected relatives from 2 families (PMID: 24368159), and has been Identified in 0.014% (2/13914) of African chromosomes and 0.003% (3/102956) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs148789453). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In vitro functional studies provide some evidence that the p.Leu238Gln variant may impact protein function (PMID: 15300847). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The presence of this variant in combination with reported pathogenic variants in 5 individuals with MPS increases the likelihood that the p.Leu238Gln variant is pathogenic (VariationID: 11908, 222994; PMID: 24368159). The phenotype of individuals compound heterozygous for this variant is highly specific for MPS based on alpha-L-iduronidase activity being <1%, consistent with disease (PMID: 15300847). In summary, this variant meets criteria to be classified as pathogenic for MPS in an autosomal recessive manner based on the presence of the variant in combination with known pathogenic variants, functional studies, cosegregation, and the phenotype of individuals with the variant and MPS being highly specific for IDUA. ACMG/AMP Criteria applied: PM3_strong, PS3_moderate, PM2_supporting, PP3, PP4, PP1 (Richards 2015). - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 31, 2022 | Published functional studies demonstrate that the L238Q variant causes reduced IDUA activity and protein levels when expressed in Chinese hamster ovary (CHO) cells (Yogalingam et al., 2004); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 15300847, 24368159, 26260077, 31194252) - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 07, 2020 | - - |
IDUA-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 18, 2024 | The IDUA c.713T>A variant is predicted to result in the amino acid substitution p.Leu238Gln. This variant was reported along with second variant in several individuals with Mucopolysaccharidosis type 1 (Yogalingam et al. 2004. PubMed ID: 15300847; Ahmed et al. 2013. PubMed ID: 24368159). In vitro functional study demonstrated that this variant reduces IDUA activity to 5.88% of normal enzyme activity (Table 3, Yogalingam et al. 2004. PubMed ID: 15300847). Alternative variant at the same codon p.Leu238Arg has been observed in an individual with Mucopolysaccharidosis type 1 (Wang et al. 2011. PubMed ID: 21480867). This variant is reported in 0.014% of alleles in individuals of African descent in gnomAD. This variant is interpreted as pathogenic. - |
Hurler syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Aug 10, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;.;D;D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T;.;.;.
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;.;.;.;.
MutationTaster
Benign
D;D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D;D
Sift4G
Uncertain
D;D;D;D;D
Polyphen
D;.;.;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at